2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯 | 848357-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯
• 英文名称: (1-(tert-butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-yl)boronic acid
• 英文别名: [6-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
• CAS: 848357-46-0
• 化学式: C₁₅H₁₈BNO₆
• 分子量: 319.122
• InChiKey: KQMBSTUEOCJFKS-UHFFFAOYSA-N

物化性质

• 沸点：
  501.6±60.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.89
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-6-(methoxycarbonyl)indole-2-boronic acid
Synonyms: 1-(t-Butoxycarbonyl)-6-(methoxycarbonyl)-1H-indol-2-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-6-(methoxycarbonyl)indole-2-boronic acid
CAS number: 848357-46-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H18BNO6
Molecular weight: 319.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium phosphate 、 水 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.25h， 生成 2-(6,6-dimethyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indole-6-carboxylic acid
  参考文献：
  名称：

  INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF

  摘要：

  提供了一种用于治疗或预防炎症性疾病、过敏性疾病、自身免疫性疾病、移植排斥等的药剂。该药剂包括以下式[I]所代表的化合物或其药用可接受的盐，或其溶剂化合物：其中每个符号如规范中所述。

  公开号：

  US20110306599A1
• 作为产物：
  描述：

  吲哚-6-甲酸甲酯 在 4-二甲氨基吡啶 硼酸三异丙酯 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 4.5h， 生成 2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯
  参考文献：
  名称：

  INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF

  摘要：

  提供了一种用于治疗或预防炎症性疾病、过敏性疾病、自身免疫性疾病、移植排斥等的药剂。该药剂包括以下式[I]所代表的化合物或其药用可接受的盐，或其溶剂化合物：其中每个符号如规范中所述。

  公开号：

  US20110306599A1
• 作为试剂：
  描述：

  2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯 、 3-碘-1H-噻吩并[3,2-C]吡唑-1-羧酸叔丁酯 、 二氯甲烷 、 Dicaesio carbonate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride solid 、 乙腈 、 水 、 2-硼-1H-吲哚-1,6-二羧酸-1-(1,1-二甲基乙基)6-甲酯 、 氮气 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 silica gel 、 mixture 、 二氯甲烷 、 正庚烷 、 2-(1-tert-butoxycarbonyl-1H-thieno[3,2-c]pyrazol-3-yl)indole-1,6-dicarboxylic acid 1-tert-butyl ester 6-methyl ester 作用下， 以 乙酸乙酯 、 dioxane-water 为溶剂， 反应 3.0h， 以to afford 2-(1-tert-butoxycarbonyl-1H-thieno[3,2-c]pyrazol-3-yl)-indole-1,6-dicarboxylic acid 1-tert-butyl ester 6-methyl ester [1.68 g, 50%, Intermediate (36)] as white foam的产率得到2-(1-tert-butoxycarbonyl-1H-thieno[3,2-c]pyrazol-3-yl)indole-1,6-dicarboxylic acid 1-tert-butyl ester 6-methyl ester
  参考文献：
  名称：

  Thienopyrazoles

  摘要：

  公式I的噻唑吡啶，其制备方法，包含这些化合物的制药组合物，以及它们在治疗能够通过抑制蛋白激酶来调节的疾病状态中的制药用途，特别是白细胞介素-2诱导的酪氨酸激酶（ITK）的抑制。

  公开号：

  US07518000B2

文献信息

• [EN] THIENOPYRAZOLES<br/>[FR] THIENOPYRAZOLES
  申请人：AVENTIS PHARMA INC

  公开号：WO2005026175A1

  公开（公告）日：2005-03-24

  Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).

  噻唑并吡唑类化合物，其制备方法，包含这些化合物的药物组合物，以及它们在治疗可通过抑制蛋白激酶，特别是白细胞介素-2诱导酪氨酸激酶（ITK）而调节的疾病状态中的药用。
• [EN] SELECTIVE LIGANDS FOR TAU AGGREGATES<br/>[FR] LIGANDS SÉLECTIFS POUR AGRÉGATS TAU
  申请人：KARIN & STEN MORTSTEDT CBD SOLUTIONS AB

  公开号：WO2019197502A1

  公开（公告）日：2019-10-17

  The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate.The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy,or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

  该发明提供了化合物的结构式(I)：或其药学上可接受的盐、酯、酰胺或碳酸酯，或此类酯、酰胺或碳酸酯的盐。该发明还提供了化合物的结构式(I)的用途和包括化合物的结构式(I)的组合物，包括利用这些化合物检测tau沉积物的用途，以及将这些化合物和组合物用作诊断剂在诊断或监测疾病或障碍的进展，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症，或用于预防或治疗疾病或障碍，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症。
• INHIBITING FATTY ACID SYNTHASE (FASN)
  申请人：Forma Therapeutics, Inc.

  公开号：EP3636637A1

  公开（公告）日：2020-04-15

  The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

  本公开涉及FASN的抑制剂。这些化合物可用于治疗与FASN抑制相关的疾病或疾病。例如，本公开涉及用于抑制FASN的化合物和组合物，治疗、预防或改善与FASN抑制相关的疾病或疾病的方法，以及这些化合物的合成方法。
• [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR)<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR D'HYDROCARBURES ARYLE (AHR)
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：WO2020021024A1

  公开（公告）日：2020-01-30

  The present invention relates to bicyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds. A-B-L-C (I)

  本发明涉及能够作为芳香烃受体（AhR）调节剂的双环化合物，特别是作为AhR拮抗剂。该发明进一步涉及利用这些化合物通过结合所述芳香烃受体来治疗和/或预防疾病和/或症状的用途。A-B-L-C（I）
• Copper-Mediated Radical Trifluoromethylation of Unsaturated Potassium Organotrifluoroborates
  作者：Marc Presset、Daniel Oehlrich、Frederik Rombouts、Gary A. Molander

  DOI：10.1021/jo4023233

  日期：2013.12.20

  Copper-mediated trifluoromethylation of unsaturated organotrifluoroborates with the Langlois reagent (NaSO2CF3) and TBHP allows the introduction of trifluoromethyl groups into a variety of organic substructures. The reactions are easy to set up, the conditions are mild and general, and the process provides access to trifluoromethylated alkynes, alkenes, arenes, and heteroarenes in fair to good yields

  铜介导的不饱和有机三氟硼酸盐与 Langlois 试剂 (NaSO 2 CF 3 ) 和 TBHP 的三氟甲基化允许将三氟甲基引入各种有机亚结构中。该反应易于建立，条件温和且通用，并且该方法提供了获得三氟甲基化炔烃、烯烃、芳烃和杂芳烃的途径，收率相当到良好。